<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486263</url>
  </required_header>
  <id_info>
    <org_study_id>11-00734</org_study_id>
    <secondary_id>R01DK068158</secondary_id>
    <nct_id>NCT02486263</nct_id>
  </id_info>
  <brief_title>Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial</brief_title>
  <acronym>GMT</acronym>
  <official_title>Pathophysiology of the Aerodigestive Reflex in Infants: GERD Management Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sudarshan Jadcherla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of the investigator's study is to evaluate the causes of and treatment&#xD;
      for feeding difficulty in infants with Gastro-esophageal Reflux Disease (GERD). New&#xD;
      treatments can be possible only if the cause is known. Many infants have GERD and feeding&#xD;
      difficulties, such as sucking and swallowing problems, vomiting, or delayed emptying of the&#xD;
      stomach. Some of these infants have difficulty in protecting their airway during feeding or&#xD;
      during reflux, and as a result can breathe fluid into their lungs or hold their breath. Most&#xD;
      GERD treatments are done based on experience, but there is no scientific proof that these&#xD;
      methods work for infants. GERD and feeding difficulties can lead to longer hospitalization&#xD;
      and more stress for the family.&#xD;
&#xD;
      In this clinical trial, the investigators are developing new methods to help with diagnosis&#xD;
      as well as defining better treatment strategies in relieving GERD and GERD complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal reflux disease (GERD) and its troublesome complications constitute serious&#xD;
      diagnostic and management challenges to the development of safe feeding and airway protection&#xD;
      strategies among infants convalescing in the neonatal intensive care units; thus contributing&#xD;
      to prolonged lengths of stay, recurrent hospitalizations, and death. GERD is frequently&#xD;
      diagnosed by inadequate criteria, and the relative risks, benefits and indications of GERD&#xD;
      therapies are unclear. Significant gaps in knowledge exist in understanding the complex&#xD;
      causal or adaptive aerodigestive protective reflex mechanisms implicated in GERD in infants.&#xD;
      The long-term goal is to improve digestive health, nutrition, and infant development through&#xD;
      the design of simplified personalized treatment paradigms by better understanding the&#xD;
      pathophysiology of aerodigestive reflexes.&#xD;
&#xD;
      The current objective is to conduct a prospective single center randomized blinded controlled&#xD;
      trial comparing the short term effects of the investigators innovative feeding strategy&#xD;
      bundle (study approach) versus standard feeding approach (conventional approach).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CLINICAL OUTCOME OF FEEDING SUCCESS</measure>
    <time_frame>Up to 5 weeks after enrollment</time_frame>
    <description>The primary endpoint is the feeding success defined as achieving full oral feeds (defined as no need for tube feeds to maintain hydration and nutrition) and/or a &gt;/= 6 point decrease from baseline symptom score as described by the Infant-Gastro-Esophageal Reflux Questionnaire-Revised. The minimum score is 0 (no symptoms) and the maximum score is 42 (maximum symptoms). Any total score greater than or equal to 16 is considered abnormal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MOTILITY OUTCOMES: Presence of Esophageal Peristaltic Reflexes</measure>
    <time_frame>5 weeks</time_frame>
    <description>This is part of Aim 2 of this RCT, which is a mechanistic outcome designed to understand the reasons for the clinical outcome. Presence of peristaltic reflex mechanisms elicited upon esophageal provocation during esophageal manometry were compared within the groups, week-5 vs. week-0. Odds ratios (ORs) with 95% confidence interval (CI) are reported from Generalized Estimation Equation models.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CLINICAL OUTCOMES: Growth Outcome Measure</measure>
    <time_frame>at 5 weeks</time_frame>
    <description>Growth: The investigators will measure and track weight growth velocity during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLINICAL OUTCOME: Development Outcome Measures</measure>
    <time_frame>Up to 1 year age</time_frame>
    <description>Feeding Milestones: The investigators will track feeding method at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLINICAL OUTCOME: Respiratory Outcome Measures</measure>
    <time_frame>at discharge</time_frame>
    <description>Supplemental oxygen requirement at discharge was recorded for both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study Arm - acid suppression plus feeding bundle</intervention_name>
    <description>Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
    <arm_group_label>Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional arm - acid suppression only</intervention_name>
    <description>-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)</description>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized infants with aerodigestive or GERD symptoms&#xD;
&#xD;
          -  Gestational age ≤42 weeks&#xD;
&#xD;
          -  Premature infants are eligible at 34 weeks postmenstrual age (PMA)&#xD;
&#xD;
          -  Enteral or Oral Fed&#xD;
&#xD;
          -  Average daily total feeding volume ≥ 150ml/kg/day&#xD;
&#xD;
          -  Room air or supplemental oxygen of ≤1 liter/minute (LPM) and/or ≤ 35% by nasal cannula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known genetic, metabolic or syndromic disease&#xD;
&#xD;
          -  Neurological diseases such as Grade 3 or 4 intraventricular hemorrhage (IVH) or&#xD;
             intracranial hemorrhage (ICH) and perinatal asphyxia&#xD;
&#xD;
          -  Gastrointestinal malformations and surgical gastrointestinal conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>34 Weeks</minimum_age>
    <maximum_age>60 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudarshan R Jadcherla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Research Institute at Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jadcherla SR, Hasenstab KA, Wei L, Osborn EK, Viswanathan S, Gulati IK, Slaughter JL, Di Lorenzo C. Role of feeding strategy bundle with acid-suppressive therapy in infants with esophageal acid reflux exposure: a randomized controlled trial. Pediatr Res. 2021 Feb;89(3):645-652. doi: 10.1038/s41390-020-0932-4. Epub 2020 May 7.</citation>
    <PMID>32380509</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <results_first_submitted>June 5, 2020</results_first_submitted>
  <results_first_submitted_qc>July 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2020</results_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sudarshan Jadcherla</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>infant</keyword>
  <keyword>esophagitis</keyword>
  <keyword>neonate</keyword>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02486263/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02486263/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study</title>
          <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study: -Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
        </group>
        <group group_id="P2">
          <title>Conventional</title>
          <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population is the same as the participant assignment.</population>
      <group_list>
        <group group_id="B1">
          <title>Study</title>
          <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study: -Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
        </group>
        <group group_id="B2">
          <title>Conventional</title>
          <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Chronological age at time of inception</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" spread="4.3"/>
                    <measurement group_id="B2" value="11.1" spread="4.5"/>
                    <measurement group_id="B3" value="10.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CLINICAL OUTCOME OF FEEDING SUCCESS</title>
        <description>The primary endpoint is the feeding success defined as achieving full oral feeds (defined as no need for tube feeds to maintain hydration and nutrition) and/or a &gt;/= 6 point decrease from baseline symptom score as described by the Infant-Gastro-Esophageal Reflux Questionnaire-Revised. The minimum score is 0 (no symptoms) and the maximum score is 42 (maximum symptoms). Any total score greater than or equal to 16 is considered abnormal.</description>
        <time_frame>Up to 5 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study: -Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
          </group>
        </group_list>
        <measure>
          <title>CLINICAL OUTCOME OF FEEDING SUCCESS</title>
          <description>The primary endpoint is the feeding success defined as achieving full oral feeds (defined as no need for tube feeds to maintain hydration and nutrition) and/or a &gt;/= 6 point decrease from baseline symptom score as described by the Infant-Gastro-Esophageal Reflux Questionnaire-Revised. The minimum score is 0 (no symptoms) and the maximum score is 42 (maximum symptoms). Any total score greater than or equal to 16 is considered abnormal.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="19" upper_limit="49"/>
                    <measurement group_id="O2" value="44" lower_limit="28" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <p_value_desc>The threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MOTILITY OUTCOMES: Presence of Esophageal Peristaltic Reflexes</title>
        <description>This is part of Aim 2 of this RCT, which is a mechanistic outcome designed to understand the reasons for the clinical outcome. Presence of peristaltic reflex mechanisms elicited upon esophageal provocation during esophageal manometry were compared within the groups, week-5 vs. week-0. Odds ratios (ORs) with 95% confidence interval (CI) are reported from Generalized Estimation Equation models.</description>
        <time_frame>5 weeks</time_frame>
        <population>Participants must have motility evaluations completed at week 0 and week 5 and have PPI washout period prior to week 5 evaluation (49 infants had follow up motility studies at week 5 of whom 40 infants had PPI washout while the other 9 remained on PPI due to parental refusal to stop).</population>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study Arm - acid suppression plus feeding bundle: -Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.&#xD;
Conventional arm - acid suppression only: -Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>MOTILITY OUTCOMES: Presence of Esophageal Peristaltic Reflexes</title>
          <description>This is part of Aim 2 of this RCT, which is a mechanistic outcome designed to understand the reasons for the clinical outcome. Presence of peristaltic reflex mechanisms elicited upon esophageal provocation during esophageal manometry were compared within the groups, week-5 vs. week-0. Odds ratios (ORs) with 95% confidence interval (CI) are reported from Generalized Estimation Equation models.</description>
          <population>Participants must have motility evaluations completed at week 0 and week 5 and have PPI washout period prior to week 5 evaluation (49 infants had follow up motility studies at week 5 of whom 40 infants had PPI washout while the other 9 remained on PPI due to parental refusal to stop).</population>
          <units>odds ratio, week-5 vs. week-0</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.3" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.4" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Generalized Estimation Equation (GEE) model was used for the comparison of differences between intervention groups from week 0 to week 5 for peristaltic response frequency.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <p_value_desc>Used Bonferroni adjustment for multiple comparisons. Threshold for statistical significance was p&lt;0.05</p_value_desc>
            <method>Generalized Estimation Equation</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Data presented as OR (95% CI) using Generalized Estimation Equation (GEE) model with Conventional as reference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLINICAL OUTCOMES: Growth Outcome Measure</title>
        <description>Growth: The investigators will measure and track weight growth velocity during the study period</description>
        <time_frame>at 5 weeks</time_frame>
        <population>Weight not available for three patients in conventional and one patient in study group at time 2</population>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study: -Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
          </group>
        </group_list>
        <measure>
          <title>CLINICAL OUTCOMES: Growth Outcome Measure</title>
          <description>Growth: The investigators will measure and track weight growth velocity during the study period</description>
          <population>Weight not available for three patients in conventional and one patient in study group at time 2</population>
          <units>grams/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="11.1"/>
                    <measurement group_id="O2" value="26.5" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Weight velocity in grams/day</non_inferiority_desc>
            <p_value>0.64</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLINICAL OUTCOME: Development Outcome Measures</title>
        <description>Feeding Milestones: The investigators will track feeding method at 1 year.</description>
        <time_frame>Up to 1 year age</time_frame>
        <population>Those subjects with follow up data available at 1 year of age</population>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study: -Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
          </group>
        </group_list>
        <measure>
          <title>CLINICAL OUTCOME: Development Outcome Measures</title>
          <description>Feeding Milestones: The investigators will track feeding method at 1 year.</description>
          <population>Those subjects with follow up data available at 1 year of age</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PO</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transition (PO + tube)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tube</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLINICAL OUTCOME: Respiratory Outcome Measures</title>
        <description>Supplemental oxygen requirement at discharge was recorded for both groups</description>
        <time_frame>at discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study: -Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
          </group>
        </group_list>
        <measure>
          <title>CLINICAL OUTCOME: Respiratory Outcome Measures</title>
          <description>Supplemental oxygen requirement at discharge was recorded for both groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>Threshold for statistical significance &lt;0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 5 weeks during the study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study</title>
          <description>Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions&#xD;
Study: -Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)&#xD;
Total fluid volume restriction (120-140 milliliters/kilogram/day)&#xD;
Feeding duration over 30 minutes&#xD;
Infant feeds with right side down&#xD;
Infant is placed on back following feeds</description>
        </group>
        <group group_id="E2">
          <title>Conventional</title>
          <description>Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sudarshan Jadcherla</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>614-355-6643</phone>
      <email>sudarshan.jadcherla@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

